more

CRISPR Therapeutics (CRSP)

(Delayed Data from NSDQ)

$51.62 USD

-0.26 (-0.50%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $51.63 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5 2

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Zacks News

Booming Gene Editing Market to Pep Up These 5 Biotech Stocks

by Zacks Equity Research Published on October 12,2020

Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.

The Innovative Future Of ETFs

by Daniel Laboe Published on October 09,2020

Ark Invest is driving a new generation of actively managed ETFs

Big October Winners: CRISPR, Alteryx, NVIDIA, Quidel

by Kevin Cook Published on October 07,2020

Two women will share the Nobel prize for a gene editing technology that will change the world.

CRISPR Therapeutics Gene Therapy CTX001 Gets PRIME Status

by Zacks Equity Research Published on September 23,2020

CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals' CRISPR/Cas9 gene-editing therapy candidate, CTX001, gets Priority Medicines designation for treating sickle cell disease.

biotechs

CRISPR Stocks: Buy or Trade?

by Kevin Cook Published on September 09,2020

Gene editing will dramatically transform medicine and life, so should you just buy-and-hold the stocks?

Vertex Seeks Nod for Cystic Fibrosis Drugs for Rare Mutations

by Zacks Equity Research Published on September 02,2020

Vertex's (VRTX) sNDAs seek approval of Trikafta, Symdeko, and Kalydeco for additional rare mutations in the CFTR genes.

pharmaceuticals

CRISPR Therapeutics AG (CRSP) Up 2.9% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research Published on August 26,2020

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CRSPNegative Net Change

CRISPR Therapeutics (CRSP) Surges: Stock Moves 6% Higher

by Zacks Equity Research Published on August 20,2020

CRISPR Therapeutics (CRSP) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

medical

Vertex (VRTX) Q2 Earnings & Sales Beat, Revenue Guidance Up

by Zacks Equity Research Published on July 31,2020

Vertex (VRTX) raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research Published on July 27,2020

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -41.30% and -99.81%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

CRSPNegative Net Change

Will CRISPR Therapeutics AG (CRSP) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research Published on July 27,2020

CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CRSPNegative Net Change

What's in Store for CRISPR (CRSP) This Earnings Season?

by Zacks Equity Research Published on July 27,2020

CRISPR Therapeutics (CRSP) is developing its lead gene-editing candidate for thalassemia and sickle cell disease. The company is expected to provide an update on its progress on the earnings call.

biotechs

CRISPR Therapeutics (CRSP) Surges: Stock Moves 6.8% Higher

by Zacks Equity Research Published on July 02,2020

CRISPR Therapeutics (CRSP) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

3 Strong Pharmaceutical and Biotech Stocks to Buy for Coronavirus Immunity

by Benjamin Rains Published on June 01,2020

Let's dive into three large-cap pharmaceutical and biotech stocks that appear set to grow during the pandemic-induced downturn and the eventual recovery...

Why Is CRISPR Therapeutics AG (CRSP) Up 22.9% Since Last Earnings Report?

by Zacks Equity Research Published on May 28,2020

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CRSPNegative Net Change

Bull of the Day: Vertex Pharma (VRTX)

by Kevin Cook Published on May 19,2020

While COVID-19 interrupts clinical trials, the champ of cystic fibrosis is about to repeat another year of 37% revenue growth

Chart Radar: Buy Software, Sell Banks

by Kevin Cook Published on May 13,2020

If a bigger pullback is unfolding in this over-valued market, now is the time to plan your big dip buys.

Vertex (VRTX) Q1 Earnings Beat, Trikafta Drives CF Revenues

by Zacks Equity Research Published on April 30,2020

Vertex (VRTX) rides high on earnings and revenue beat in Q1.The company raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research Published on April 28,2020

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -5.50% and -97.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

CRSPNegative Net Change

Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research Published on April 27,2020

CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CRSPNegative Net Change

What Makes CRISPR Therapeutics AG (CRSP) a New Buy Stock

by Zacks Equity Research Published on April 27,2020

CRISPR Therapeutics AG (CRSP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).